Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05588648 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
A Phase 1 study of Osteosarcoma, sponsored by MedPacto.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 3
- Study locations
NCT05588648: Recruiting Phase 1 study of Osteosarcoma, sponsored by MedPacto.
NCT05588648 is a Phase 1 study of Osteosarcoma that is actively recruiting participants, run by MedPacto. The registered enrollment target is 48 participants, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05588648, a Phase 1 study of Osteosarcoma, is actively recruiting participants, sponsored by MedPacto.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 3
- Study locations
Study Summary
MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 12 years of age and older who meet the criteria for study enrollment.
Primary Outcome
Maximum tolerated dose (MTD) and recommended dose (RD)
Conditions Studied
Interventions
- DRUG Vactosertib
Study Locations (3)
Other
- National Cancer Center - Gyeonggi-do
- Korea Institute of Radiological & Medical Sciences - Seoul
Ohio
- UH Rainbow Babies & Children's Hospital - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What NCT05588648 shows while recruiting
NCT05588648 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Osteosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Vactosertib is the first listed.
NCT05588648 reports a single indexed study location in Other, Ohio.
Frequently Asked Questions
What is clinical trial NCT05588648 about?
NCT05588648 is a clinical study titled "Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma". MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 12 yea...
What is the current status of trial NCT05588648?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-05-01. Estimated completion is 2025-12.
What conditions does trial NCT05588648 study?
This clinical trial studies the following conditions: Osteosarcoma.
What interventions are being tested in trial NCT05588648?
The interventions under investigation include: Vactosertib (DRUG).
Who is sponsoring clinical trial NCT05588648?
This trial is sponsored by MedPacto, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05588648 being conducted?
This trial has 3 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05588648's enrollment target sits among peer trials
48 20th of 46 higher than 26 of 46 other Osteosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Losartan + Sunitinib in Treatment of Osteosarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI